Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for MEK inhibitors
Most Correlated Studies
- Colorectal cancer cells treated with tankyrases and MEK inhibitors
- Gastric cancer cells treated with MEK inhibitor PD0325901
- Cancer cell lines treated with BET inhibitor GSK525762 and/or MEK inhibitor trametinib
- Metastatic melanoma cells BRAF-V600E with MEK inhibitor resistance and NICD overexpression
- Monocytes from blood treated with TPL2 or MEK inhibitors in the presence or absence of LPS
Most Relevant Literature
- Non-'classical' MEKs: A review of MEK3-7 inhibitors.
- BILATERAL VISUAL FIELD DEFECTS IN A PATIENT TREATED WITH THE MEK AND BRAF INHIBITORS TRAMETINIB AND …
- Effect of ERK1/2 Signaling Pathway Inhibitor PD98059 on the Expression of Ras, BRaf, MEK, ERK1/2 in …
- Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
- Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
Most Relevant Clinical Trials
- A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumo…
- MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Ac…
- MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treati…
- Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Me…
- Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS …
